Pyxis Oncology, Inc. (PYXS): Depreciation & Amortization
$4.51M
Year ended 2025-12-31
$4.18M
Trailing 12 months to 2026-06-30
+85.3%
3-year compound annual growth
+57.3%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.51M | +51.3% | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | $2.98M | +54.7% | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | $1.93M | +171.8% | 2025-03-18, From 2023-01-01 |
| 2022-12-31 | $709.0K | +9.6% | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $647.0K | +38.0% | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | $469.0K | n/a | 2022-03-29, From 2020-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $4.51M | +51.3% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $192.0K | -42.5% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $1.90M | -34.5% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $600.0K | +20.0% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $39.0K | +77.3% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $1.71M | -3.4% |
| uniQure N.V. (QURE) | 2025-12-31 | $14.76M | +16.8% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $1.91M | +0.7% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $109.0K | -53.2% |
Compare PYXS, CVSI, TNXP, EVMN side by side · Screen every company in Pharmaceutical Preparations ↗